GSK’s Tanzeum Launch Marks The Big Pharma’s Return To Diabetes
This article was originally published in The Pink Sheet Daily
Executive Summary
GSK expects Tanzeum will be one of its “core big six” drugs despite the fact that it is the fourth GLP-1 to market. VP-General Medicines Cheryl MacDiarmid discussed GSK’s return to diabetes in an interview.